Amgen(US:AMGN) Investing·2026-02-05 08:43Group 1 - The article provides a market analysis of Amgen Inc., highlighting its recent performance and strategic initiatives [1] - Amgen's revenue for the last quarter reached $6.5 billion, reflecting a year-over-year increase of 5% [1] - The company has seen a significant rise in sales of its flagship drug, Enbrel, contributing to overall growth [1] Group 2 - Amgen's research and development expenditures have increased by 10% this year, indicating a strong commitment to innovation [1] - The company is expanding its pipeline with several new drug candidates expected to enter clinical trials in the coming months [1] - Amgen's stock price has shown volatility, influenced by market trends and competitive pressures within the biotechnology sector [1]